- Home
- EDF vs SGMO Comparison
EDF vs SGMO Comparison
Compare EDF & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- SGMO
- Stock Information
- Founded
- EDF 2010
- SGMO 1995
- Country
- EDF United States
- SGMO United States
- Employees
- EDF N/A
- SGMO N/A
- Industry
- EDF Investment Managers
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDF Finance
- SGMO Health Care
- Exchange
- EDF Nasdaq
- SGMO Nasdaq
- Market Cap
- EDF 148.8M
- SGMO 122.8M
- IPO Year
- EDF N/A
- SGMO 2000
- Fundamental
- Price
- EDF $5.06
- SGMO $0.54
- Analyst Decision
- EDF
- SGMO Buy
- Analyst Count
- EDF 0
- SGMO 6
- Target Price
- EDF N/A
- SGMO $4.50
- AVG Volume (30 Days)
- EDF 160.6K
- SGMO 6.1M
- Earning Date
- EDF 01-01-0001
- SGMO 08-05-2025
- Dividend Yield
- EDF 13.14%
- SGMO N/A
- EPS Growth
- EDF N/A
- SGMO N/A
- EPS
- EDF N/A
- SGMO N/A
- Revenue
- EDF N/A
- SGMO $63,756,000.00
- Revenue This Year
- EDF N/A
- SGMO N/A
- Revenue Next Year
- EDF N/A
- SGMO N/A
- P/E Ratio
- EDF N/A
- SGMO N/A
- Revenue Growth
- EDF N/A
- SGMO 239.92
- 52 Week Low
- EDF $3.51
- SGMO $0.30
- 52 Week High
- EDF $5.50
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- EDF 60.99
- SGMO 54.59
- Support Level
- EDF $4.96
- SGMO $0.41
- Resistance Level
- EDF $5.07
- SGMO $0.51
- Average True Range (ATR)
- EDF 0.06
- SGMO 0.05
- MACD
- EDF -0.00
- SGMO 0.01
- Stochastic Oscillator
- EDF 76.47
- SGMO 74.39
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.